Skip to main content
Premium Trial:

Request an Annual Quote

Agilent Sheds Hycor Biomedical Business

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Private equity firm Linden LLC has paid an undisclosed sum to purchase the Hycor Biomedical business of Agilent Technologies.

Hycor, which specializes in allergy, autoimmune, and urinalysis diagnostics, became part of Agilent through that firm's 2007 acquisition of Stratagene. Hycor had only been part of Stratagene for a few years before the deal with Agilent.

"We believe Hycor has great opportunities outside of the Agilent portfolio," Nick Roelofs, president of Agilent's Life Sciences Group, said in a statement. ""Hycor is an innovative, profitable and growing business, but it does not fit the core focus of our life science business."

Agilent officials declined to provide revenue figures for the Hycor business.

The Scan

Tens of Millions Saved

The Associated Press writes that vaccines against COVID-19 saved an estimated 20 million lives in their first year.

Supersized Bacterium

NPR reports that researchers have found and characterized a bacterium that is visible to the naked eye.

Also Subvariants

Moderna says its bivalent SARS-CoV-2 vaccine leads to a strong immune response against Omicron subvariants, the Wall Street Journal reports.

Science Papers Present Gene-Edited Mouse Models of Liver Cancer, Hürthle Cell Carcinoma Analysis

In Science this week: a collection of mouse models of primary liver cancer, and more.